跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XOLAIR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
XOLAIR
Authorized
STANDARD
XOLAIR
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
3e13c37e5afc8d75
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
3e13c37e5afc8d75
Drug Approval Canada Name
XOLAIR
Product Name
XOLAIR
Status
Marketed
Status Date
2017-07-06
Original Market Date
2017-07-06
Din
02459795
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
90:28.16.92
Atc Original
R03DX05 OMALIZUMAB
Atc Name
r 03 dx 05
Aig Number
0150422001
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
OMALIZUMAB
150 MG / 1 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
3e13c37e5afc8d75
Type
Standard
Back to Health Canada Approvals